HyBryte™ (SGX301)
Cutaneous T-Cell Lymphoma (CTCL)
Phase 3NDA Preparation
Key Facts
About Soligenix
Soligenix operates through two core business segments: a Specialized BioTherapeutics division developing treatments for rare diseases, and a Public Health Solutions division focused on medical countermeasures against biological and chemical threats. The company's lead candidate, HyBryte™ (SGX301), has demonstrated positive Phase 3 results for cutaneous T-cell lymphoma and is positioned as a potential first-in-class photodynamic therapy. With a diversified pipeline spanning oncology, infectious diseases, and biodefense, Soligenix leverages government grants and strategic collaborations to advance its development programs while managing financial resources carefully.
View full company profileTherapeutic Areas
Other Cutaneous T-Cell Lymphoma (CTCL) Drugs
| Drug | Company | Phase |
|---|---|---|
| LYMPHIR™ (E7777) | Citius Pharmaceuticals | Approved |